MET and neoplasm: Applying our pre‐clinical findings, we then treated two patients (one with a non‐small‐cell lung cancer and one with a renal cell carcinoma) whose tumours harboured these previously uncharacterised MET alterations with cabozantinib, a type II MET TKI, and observed clinical responses.